Most Read Articles
Elvira Manzano, 29 May 2018
Repeat doses of the intrathecal antisense oligonucleotide nusinersen in children with infantile-onset spinal muscular atrophy (SMA) continue to demonstrate safety, according to  early data from the phase III SHINE extension study, bringing considerable hope to the SMA community.
Audrey Abella, 29 Aug 2018
The combination of the alkylating nitrosourea compound lomustine and the monoclonal antibody bevacizumab prolonged progression-free survival (PFS) in patients with progressive glioblastoma compared with either drug alone, a meta-analysis has shown.
31 Aug 2018
New drug applications approved by US FDA as of 16 - 31 August 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
29 Aug 2018
The risk of traumatic brain injury (TBI) is elevated in young people with attention-deficit/hyperactivity disorder (ADHD), though long-term ADHD medication can reduce this risk, a recent study has found.

Regions of brain metastasis vary by breast cancer subtypes

25 Nov 2017
Radiologists interpret complex medical imaging to arrive at an accurate diagnosis

Different breast cancer subtypes appear to show different spatial distributions of brain metastasis (BM), with luminal type and human epidermal growth factor receptor 2 (HER2)-positive breast cancers showing BM dominance in the occipital lobe and cerebellum, suggests a recent study.

Brain magnetic resonance (MR) images of 100 breast cancer patients with confirmed BM were retrospectively analysed. Distribution patterns of BM were compared among and within groups, which were defined by biological subtype of the primary tumour.

In the study sample, 24 patients had triple-negative primary breast cancers (mean age at diagnosis 46.45±10.88 years), 48 were HER2-positive (mean age at diagnosis 49.5±11.45 years) and 28 had luminal breast cancer (mean age at diagnosis 46.75±9.73 years).

While the mean number of BM per patient did not differ among the subtypes (5.04±6.37, 4.71±6.58 and 5.35±6.69), both triple negative (23.5±23.36 months) and HER2-positive (19±29.54 months) cancers had significantly shorter time to BM than luminal breast cancers (42±45.51 months; p<0.01).

In intergroup analysis, researchers found that BM from triple-negative breast cancers was more likely to occur in the limbic region, parietal lobe and frontal lobe (corrected p<0.05) compared to the other cancer subtypes.

In contrast, HER2-positive breast cancers were less likely to have BM in the frontal lobe and subcortical regions, while BM from luminal type breast cancers were less likely to happen in the cerebellum, subcortical region and occipital lobe compared with the other cancer subtypes (corrected p<0.05).

Editor's Recommendations
Most Read Articles
Elvira Manzano, 29 May 2018
Repeat doses of the intrathecal antisense oligonucleotide nusinersen in children with infantile-onset spinal muscular atrophy (SMA) continue to demonstrate safety, according to  early data from the phase III SHINE extension study, bringing considerable hope to the SMA community.
Audrey Abella, 29 Aug 2018
The combination of the alkylating nitrosourea compound lomustine and the monoclonal antibody bevacizumab prolonged progression-free survival (PFS) in patients with progressive glioblastoma compared with either drug alone, a meta-analysis has shown.
31 Aug 2018
New drug applications approved by US FDA as of 16 - 31 August 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
29 Aug 2018
The risk of traumatic brain injury (TBI) is elevated in young people with attention-deficit/hyperactivity disorder (ADHD), though long-term ADHD medication can reduce this risk, a recent study has found.